EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparison of the high‐dose dual therapy and standard quadruple therapy methods containing bismuth as the first line of treatment in eradicating Helicobacter pylori infection in Iran: A clinical trial study

Shahriar Nikpour, Mohammad Salehi, Maryam Abbasi, Ako Ghahremani, Sholeh Tavakoly Shiraji, Sara Abasi, Mohsen Rokni

Advances in Digestive Medicine · 2026-09 · 13 (3)

DOI: 10.1002/aid2.70042 ↗
AbstractBibliografische Angaben

Abstract

Abstract Helicobacter pylori ( H. pylori ) infection is one of the most common infections in the world, which causes various complications, including abdominal pain and cancer. There are two methods for H. pylori treatment: standard quadruple therapy with bismuth subcitrate (BQT) and high‐dose dual therapy (HDDT). This study aimed to compare these two treatment methods with each other in patients with H. pylori infection. This quasi‐randomized clinical trial study was conducted on 101 patients receiving the BQT and 105 patients with HDDT methods in Loqhman hospital in Iran. The first and second intervention groups (BQT and HDDT), respectively, were undergoing treatment with standard quadruple with amoxicillin (1 g), pantoprazole (20 mg), metronidazole (1 g), and bismuth subcitrate (240 mg) and HDDT with amoxicillin (1 g) and pantoprazole (40 mg) for 14 days. After 4 weeks, the effectiveness of the therapy methods in eradicating H. pylori was assessed by ELISA method by examining the antigen of H. pylori in feces. The mean age of patients in the BQT group was 42.2 years and in the HDDT group was 42.7 years. The 82% in the BQT group and 79% in the HDDT group had negative fecal antigens H. pylori after 2 weeks of treatment. Although the efficacy rate of HDDT treatment was relatively higher in the HDDT group, the difference between these two groups was not statistically significant ( p = .5). The study results indicated that BQT therapy is not significantly more effective than HDDT therapy, and their effects are similar.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →